Literature DB >> 32900703

Targeting Epigenetics in Lung Cancer.

Yvonne L Chao1, Chad V Pecot1.   

Abstract

The epigenetic landscape, which in part includes DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation, greatly contributes to the heterogeneity that makes developing effective therapies for lung cancer challenging. This review will provide an overview of the epigenetic alterations that have been implicated in all aspects of cancer pathogenesis and progression as well as summarize clinical applications for targeting epigenetics in the treatment of lung cancer.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 32900703      PMCID: PMC8168531          DOI: 10.1101/cshperspect.a038000

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  4 in total

1.  Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.

Authors:  Yue Zhao; Yakun Gao; Xiaodong Xu; Jiwu Zhou; He Wang
Journal:  BMC Cancer       Date:  2021-03-09       Impact factor: 4.430

2.  MGMT gene promoter methylation in humoral tissue as biomarker for lung cancer diagnosis: An update meta-analysis.

Authors:  Bizheng Chen; Xiaozhen Ying; Liming Bao
Journal:  Thorac Cancer       Date:  2021-10-15       Impact factor: 3.500

3.  A novel defined m7G regulator signature to investigate the association between molecular characterization and clinical significance in lung adenocarcinoma.

Authors:  Yi Dong; Yingge Li; Yi Yao; Qibin Song
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

4.  METTL1/WDR4-mediated m7G tRNA modifications and m7G codon usage promote mRNA translation and lung cancer progression.

Authors:  Jieyi Ma; Hui Han; Ying Huang; Chunlong Yang; Siyi Zheng; Tiancai Cai; Jiong Bi; Xiaohui Huang; Ruiming Liu; Libin Huang; Yifeng Luo; Wen Li; Shuibin Lin
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.